Антибиотикоассоциированные диареи

Клиническая Микробиология и Антимикробная Химиотерапия. 2002; 4(1):22-32

​ Малов В.А.
антибиотикоассоциированные диареи Clostridium difficile псевдомембранозный колит антибактериальная терапия
Раздел
Болезни и возбудители
Тип
Журнальная статья
Публикация
Клиническая Микробиология и Антимикробная Химиотерапия. 2002; 4(1):22-32

Аннотация

Диареи, связанные с приемом антибиотиков, представляют одну из актуальных проблем современной медицины. В настоящем обзоре рассмотрены вопросы этиологии, патогенеза и эпидемиологии антибиотикоассоциированных диарей (ААД). Представлены различные клинические варианты и особенности течения ААД. Проанализированы преимущества и недостатки различных методов микробиологической диагностики инфекции, вызванной Clostridium difficile, являющейся наиболее частой причиной развития ААД. В статье рассмотрены основные подходы к лечению Clostridium difficile-ассоциированного колита, особое внимание уделено показаниям к назначению антимикробных препаратов и выбору схем этиотропной терапии.

  • 1. Навашин С.М. Введение. Рус мед журн 1997; 5(21):1364.
  • 2. McFarland L.V. Diarrhea acquired in the hospital. Gastroenterol Clin North Am 1993; 22:563-77.
  • 3. Малов В.А., Пак С.Г., Несвижский Ю.В., Кондратьева Т.В. Диагностика антибиотикоассоциированных колитов, обусловленных Clostridium difficile. Материалы VI Российско-итальянской научной конференции "Инфекционные болезни: диагностика, лечение, профилактика". 2000; Санкт-Петербург, Россия. с. 156.
  • 4. Thielman N.M. Antibiotic-associated colitis. In: Mandell G.L., Bennett J.E., Dolin R., editors. Principles and practice of infectious diseases. 5th ed. Philadelphia: Churchill Livingstone; 2000. p. 1111-26.
  • 5. George W.L., Rolfe R.D., Finegold S.M. Clostridium difficile and its cytotoxin in feces of patients with antimicrobial agent-associated diarrhea and miscellaneous conditions. J Clin Microbiol 1982; 15:1049-53.
  • 6. Benoit R., Dorval D., Loulergue J., et al. Post-antibiotic diarrheas: role of Klebsiella oxytoca. Gastroenterol Clin Biol 1992; 16:860-4.
  • 7. Hogenauer C., Hammer H., Krejs G. Mechanisms and management of antibiotico-associated diarrhea. Clin Inf Dis 1998; 27:702-10.
  • 8. Holmberg S.D., Oslterholm M.T., Senger K.A. Drag-resistant Salmonella from animal fed antimicrobials. N Engl J Med 1984; 311:617-22.
  • 9. McDonald M., Ward P., Harvey K. Antibiotic-associated diarrhoea and methicillin-resistant Staphylococcus aureus. Med J Aust 1982; 1:462-4.
  • 10. Reinke C.M. ASHP therapeutic position statement on the preferential use of metronidazole for the treatment of Clostridium difficile-associated disease. Am J Health-Syst Pharm 1998; 55:1407-11.
  • 11. Taylor M., Ajayi F., Almond M. Enterocolitis caused by methicillin-resistant Staphylococcus aureus. Lancet 1993; 342:804.
  • 12. Prescott R.J., Harris M., Banejee S.S. Funginal infections of the small and large intestine. J Clin Pathol 1992; 45:806-11.
  • 13. Bartlett J.G. Antibiotic-associated diarrhea. N Engl J Med 2002; 346:334-9.
  • 14. Hogenauer C., Hammer H.F., Krejs G.J., Reisinger E.C. Mechanisms and management of antibiotic-associated diarrhea. Clin Infect Dis 1998; 27:702-10.
  • 15. Chassany O., Michaux A., Bergmann J.F. Drug-induced diarrhoea. Drug Saf 2000; 22:53-72.
  • 16. Riley T.V. Clostridium difficile: A pathogen of the nineties. Eur J Clin Microbiol Infect Dis 1998; 17:137-41.
  • 17. Kim K.H., Fekety R., Batts D.H., et al. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis 1981; 143:42-50.
  • 18. Larson H.E. Barclay F.E., Honour P. et all. Epidemiology of Clostridium difficile in infants. J Infect Dis 1982; 146:727-33.
  • 19. Frost F., Craun G.F., Calderon R.L. Increasing hospitalization and death possibly due to Clostridium difficile diarrheal disease. EID 1998; 4(3):619-25.
  • 20. Hirschhorn L.R., Trnka Y., Onderdonk A., et al. Epidemiology of community-acquired Clostridium difficile-associated diarrhea. J Infect Dis 1994; 169:127-33.
  • 21. McFarland L.V., Mulligan M.E., Kwok R.Y., Stamm W.E. Nosocomial acquisition of Clostridium difficile in infection. N Engl J Med 1989; 320:204-10.
  • 22. Spencer RC. The role of antimicrobial agents in the aetiology of Clostridium difficile-associated disease. J Antimicrob Chemother 1998; 41:21-7.
  • 23. Pierce P.F., Wilson R., Silwa J.J., et al. Antibiotic-associated pseudomembranous colitis: An epidemiologic investigation of claster of cases. J Infect Dis 1982; 145:269-74.
  • 24. Hutin Y., Molina J.M., Casin I., et al. Risk factors for Clostridium difficile-associated diarrhoea in HIV-infected patients. AIDS 1993; 7:1441-7.
  • 25. Hooper L.V., Wong M.H., Thelin A., et al. Molecular analysis of commensal host-microbial relationships in the intestine. Science 2001; 291:881-4.
  • 26. Small J.D. Drags used in hamsters with a review of antibiotic-associated colitis in the laboratory hamster. In: Van Hoosier G.L., McPherson C.W., editors. Laboratory Hamsters. Orlando: Academic Press; 1987. p.179-99.
  • 27. Depitre C., Delmee M., Avesani V., et al. Serogroup F strains Clostridium difficile of produce toxin B but not toxin A. J Med Mecrobiol 1993; 3:434-41.
  • 28. Hippenstiel S., Kratz T., Krull M., et al. Rho protein inhibition blocks protein kinase C translocation and activation. Biochem Biophys Res Commun 1998; 245:830-4.
  • 29. Viscidi R., Laughon B.E., Yoker R. Serum antibody response to toxin A and B of Clostridium difficile. J Infect Dis 1983; 148:93-100.
  • 30. Kelly C.P., Pothoulakis C., Orellana J., et al. Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding. Gastroenterology 1992; 102:35-40.
  • 31. Knoop F.C., Owens M., Crocker I.C. Clostridium difficile: Clinical disease and diagnosis. Clin Microbiol Rev 1993; 6:251-65.
  • 32. Manabe Y.C., Vinetz J.M., MooreR.D., et al. Clostridium difficile colitis: An efficient clinical approach to diagnosis. Ann Intern Med 1995; 123:835-40.
  • 33. Byl B., Jacobs F., Struelens M.J., Thys J.P. Extraintestinal infections Clostridium difficile. Clin Infect Dis 1995; 20:160-2.
  • 34. Do A.N., Fridkin S.K., Yechouron A., et al. Risk factors for early recurrent Clostridium difficile-associated diarrhea. Clin Infect Dis 1998; 26:954-9.
  • 35. Nair S., Yadav D., Corpuz M., et al. Clostridium difficile colitis: factors influencing treatment failure and relapse – a prospective evaluation. Am J Gastroenterol 1998; 93:1873-6.
  • 36. Kyne L., Warny M., Qamar A., Kelly C.P. Association Between Antibody Response to Toxin A and Protection Against Recurrent Clostridium difficile Diarrhoea. Lancet 2001; 357:189-93.
  • 37. Lyerly D.M., Krivan H.C., Wilkins T.D. Clostridium difficile: Its disease and toxins. Clin Microbiol Rev 1988; 1:1-18.
  • 38. Bergstein J.M., Kramer A., Wittman D.H., et al. Pseudomembranous colitis: How useful is endoscopy? Surg Endosc 1990; 4:217-9.
  • 39. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology. Practice Parameters Committee. Am J Gastroenterol 1997; 92:739-50.
  • 40. Teasley D.G., Gerding D.N., Olson M.M., et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis. Lancet 1983; 2:1043-6.
  • 41. MacLaren R., Morton T.H., Kuhl D.A. Effective management of Clostridium difficile colitis. Hosp Pharm 1997; 32:1126-32.
  • 42. Elmer G.W., McFarland L.V., Surawicz C.M., Danko L., Greenberg R.N. Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients. Aliment Pharmacol Ther 1999; 13(12):1663-8.
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились